Human C-FMS antigen binding proteins

摘要

An antibody selected from the group consisting of an antibody comprising complementarity determining regions (CDR) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3, wherein said CDRs comprise the amino acid sequences as set forth below: (a) CDRH1 comprises SEQ ID NO: 147, CDRH2 comprises SEQ ID NO: 163, CDRH3 comprises SEQ ID NO: 186, CDRL1 comprises SEQ ID NO: 193, CDRL2 comprises SEQ ID NO: 214, and CDRL3 comprises SEQ ID NO: 228, (b) CDRH1 comprises SEQ ID NO: 137, CDRH2 comprises SEQ ID NO: 150, CDRH3 comprises SEQ ID NO: 166, CDRL1 comprises SEQ ID NO: 198, CDRL2 comprises SEQ ID NO: 216, and CDRL3 comprises SEQ ID NO: 233, ( d) CDRH1 comprises SEQ ID NO: 147, CDRH2 comprises SEQ ID NO: 163, CDRH3 comprises SEQ ID NO: 186, CDRL1 comprises SEQ ID NO: 195, CDRL2 comprises SEQ ID NO: 214, and CDRL3 comprises SEQ ID NO: 228 , (e) CDRH1 comprises SEQ ID NO: 137, CDRH2 comprises SEQ ID NO: 152, CDRH3 comprises SEQ ID NO: 170, CDRL1 comprises SEQ ID NO: 198, CDRL2 com turns on SEQ ID NO: 216, and CDRL3 comprises SEQ ID NO: 233, (f) CDRH1 comprises SEQ ID NO: 147, CDRH2 comprises SEQ ID NO: 163, CDRH3 comprises SEQ ID NO: 186, CDRL1 comprises SEQ ID NO: 194 , CDRL2 comprises SEQ ID NO: 214, and CDRL3 comprises SEQ ID NO: 228, (g) CDRH1 comprises SEQ ID NO: 141, CDRH2 comprises SEQ ID NO: 156, CDRH3 comprises SEQ ID NO: 172, CDRL1 comprises SEQ ID NO : 209, CDRL2 comprises SEQ ID NO: 223, and CDRL3 comprises SEQ ID NO: 245, (i) CDRH1 comprises SEQ ID NO: 140, CDRH2 comprises SEQ ID NO: 155, CDRH3 comprises SEQ ID NO: 169, CDRL1 comprises SEQ ID NO: 202, CDRL2 comprises SEQ ID NO: 218, and CDRL3 comprises SEQ ID NO: 236, (j) CDRH1 comprises SEQ ID NO: 140, CDRH2 comprises SEQ ID NO: 155, CDRH3 comprises SEQ ID NO: 169, CDRL1 comprises SEQ ID NO: 201, CDRL2 comprises SEQ ID NO: 218, and CDRL3 comprises SEQ ID NO: 236, (k) CDRH1 comprises SEQ ID NO: 143, CDRH2 comprises SEQ ID NO: 158, CDRH3 comprises SEQ ID NO: 190 , CDRL1 comprises SEQ ID NO: 199, CDRL2 comprises SEQ ID NO: 219, and CDRL3 comprises SEQ ID NO: 237, (l) CDRH1 comprises SEQ ID NO: 137, CDRH2 comprises SEQ ID NO: 151, CDRH3 comprises SEQ ID NO: 167, CDRL1 comprises SEQ ID NO: 199, CDRL2 comprises SEQ ID NO: 217, and CDRL3 comprises SEQ ID NO: 233, (m) CDRH1 comprises SEQ ID NO: 137, CDRH2 comprises SEQ ID NO: 150, CDRH3 comprises SEQ ID NO: 173, CDRL1 comprises SEQ ID NO: 198 , CDRL2 comprises SEQ ID NO: 216, and CDRL3 comprises SEQ ID NO: 233, (n) CDRH1 comprises SEQ ID NO: 142, CDRH2 comprises SEQ ID NO: 157, CDRH3 comprises SEQ ID NO: 187, CDRL1 comprises SEQ ID NO : 206, CDRL2 comprises SEQ ID NO: 221, and CDRL3 comprises SEQ ID NO: 242, (or) CDRH1 comprises SEQ ID NO: 143, CDRH2 comprises SEQ ID NO: 158, CDRH3 comprises SEQ ID NO: 177, CDRL1 comprises SEQ ID NO: 200, CDRL2 comprises SEQ ID NO: 216, and CDRL3 comprises SEQ ID NO: 235, or (p) CDRH1 comprises SEQ ID NO: 142, CDRH2 comprises SEQ ID NO: 157, CDRH3 comprises SEQ ID NO: 176, CDRL1 comprises SEQ ID NO: 207, CDRL2 comprises SEQ ID NO: 224, and CDRL3 comprises SEQ ID NO: 243; and wherein said antibody binds to human c-fms with a KD of less than 10-8M, measured as described herein.